Recent Finacing
Recent Raise
Orbus Therapeutics is a Palo Alto late-stage biopharmaceutical company developing eflornithine for recurrent anaplastic astrocytoma, conducting the global STELLAR Phase 3 trial across 85+ centers to enroll 340 patients.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Orbus Therapeutics.
